CDCA3

Across TCGA pan-cancer cohorts, CDCA3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDCA3 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CDCA3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDCA3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, LSCC, and GBM are the cancer types where CDCA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.288	0.848	.007	13	view →
LSCC	OS	Median	II,III,IV	0.853	0.613	.027	2	view →
GBM	OS	Median	All	0.689	0.447	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CDCA3–HNSC (DFS)

Open the HNSC breakdown →